



November 13, 2014

ImmunoGen, Inc. Again Named One of The Boston Globe's Top Places to Work

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that it has been named one of The Boston Globe's Top Places to Work. The Company has received this recognition for the second consecutive year and in three of the last four years.

Daniel Junius, President and CEO, commented, "We are extremely pleased that ImmunoGen has once again been recognized as one of The Boston Globe's Top Places to Work. We believe that attracting and retaining the right employees is essential to achieving our mission of making a difference to patients with cancer."

The Boston Globe's 2014 Top Places to Work survey, conducted by WorkplaceDynamics, measured responses of employees from numerous organizations in Massachusetts to statements regarding six key factors related to employee happiness, including company direction, execution, employee connection, work load and responsibility, management, and pay and benefits. More than 73,500 individuals responded to the survey. Among survey respondents, greatest importance was placed on aspects related to employee appreciation, confidence and feeling a meaningful connection to the work. WorkplaceDynamics also found that, of all the cities surveyed, employees in the Boston area were most enthusiastic about their companies, making Boston the top of the Top Places to Work.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; the Company has also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla[®]. ImmunoGen has three wholly owned product candidates in clinical testing with additional compounds in clinical testing through the Company's partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla[®] is a registered trademark of Genentech, a member of the Roche Group.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com

or
For Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085

Source: ImmunoGen, Inc.

News Provided by Acquire Media